retatrutide when available Retatrutide, a new weight loss drug not on the market yet, is showing promising results in trials. Dr. LaPook explains it’s doing much more than what current medications can. | CBS News What Patients Should Understand Before
Description
The cormorbidities often associated with HFpEF such as obesity, diabetes mellitus, and hypertension as well as the metabolic changes associated with them are known to induce a state of inflammation that affects cardiac metabolism, as well as coronary vascular injury and ischemia [5]

Combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the weight loss and cardiometabolic benefits of GLP-1 RA [21]

Antiatherosclerotic effects of sodium-glucose cotransporter 2 inhibitors: an underrecognized piece of the big puzzle

This vegan, non-GMO supplement is produced in a GMP-certified facility for safety and consistency

And we may just be getting started
Cancer biology in diabetes
